Latham & Watkins represented Revolution Medicines, while Davis Polk advised the underwriters in the offering. Revolution Medicines, Inc. (Nasdaq: RVMD), has announced the pricing of its underwritten...
Revolution Medicines’ $230 Million Shares Offering
Chinook Therapeutics’ $105 Million Public Offering
Latham & Watkins represented the underwriters in the offering. Chinook Therapeutics, Inc. (Nasdaq: KDNY) has announced the pricing of its underwritten public offering of 6,428,572 shares...
HilleVax’s $200 Million Initial Public Offering
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
Twist Bioscience’s $250 Million Common Stock Offering
Orrick, Herrington & Sutcliffe advised Twist Bioscience, while Latham & Watkins represented the underwriters in the offering. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers...
Arcutis Biotherapeutics’ $225 Million Non-Dilutive Debt Financing
Latham & Watkins represented Arcutis in the transaction. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that...
Silver Spike Acquisition Corp. II’s $446 Million Combination With Eleusis
Davis Polk advised Silver Spike Acquisition Corp. II on the deal, while Latham & Watkins represented Eleusis. Silver Spike Acquisition Corp. II announced its approximately $446...
Thorne HealthTech’s $70 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati represented Thorne HealthTech, while Latham & Watkins represented the underwriters in the offering. Thorne HealthTech, a leader in developing innovative solutions...
Eliem Therapeutics’ $80 Million Initial Public Offering
Latham & Watkins represented the underwriters in the offering. Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to...
Icosavax’s $209.3 Million IPO
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
Absci Corporation’s $200 Million Initial Public Offering
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
Erasca’s $345 Million Initial Public Offering
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
Aligos Therapeutics’ $83.6 Million Public Offering
Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced...